

Hyphens Pharma International Limited

24 August 2021

BUY
(Maintained)

Price: S\$0.300 (as at 23 August 2021)

Target Price: S\$0.370 (+23.3%)

BBG	HYP SP
Market cap	S\$90.1m
Price (23 August 2021)	S\$0.300
52-week range	S\$0.285 – S\$0.495
Target Price	S\$0.370
Shares Outstanding	300.4m
Free Float	22.0%
Major Shareholder	Inomed Holding Pte Ltd 39.9% Tan Kia King 25.4% Tan Chwee Choon 12.7%
P/BV (06/21)	1.8x
Net Debt to EBITDA (12/21)	Net cash

Source: Company data, Bloomberg, SAC Capital

Analyst
Lim Li Jun Tracy +65 6232 3239
tljm@saccapital.com.sg

Analyst
Lam Wang Kwan +65 6232 3237
lamwk@saccapital.com.sg

Strongest 1H recorded

1HFY21 revenue was in line with our forecasts, making up 50.2% of our FY21E revenue. Net profit was higher at 71.1% of our forecasts, as gross margin generated from specialty pharma segment exceeded our expectations due to better product mix.

Revenue rose across all segments, climbing 6.1% to S\$65.4m, led by specialty pharma principals which grew 10.9% yoy from S\$31.4m to S\$34.8m, with higher demand in Vietnam, Singapore & Malaysia. Proprietary brands (+2.4%) with higher demand for Ceradan products and medical hypermart & digital (+0.4%) saw slight uptick.

Gross margin rose 3.7ppt to 37.9% in 1H21, with higher margins from the specialty pharma segment. Net profit rose 0.8% yoy to S\$4.3m. If government grants were excluded from both periods, net profit grew 22.7% from S\$3.4m to S\$4.2m.

Continue to focus on proprietary brands and internationalization efforts. The Group continues to undergo considerable R&D (S\$0.2m in 1H21, compared to S\$0.07m in 1H20), and has, in 1H, launched its Ocean Health® Eye Moist Omega supplement to promote moist eyes and healthy vision. Revenue contribution from markets outside Singapore increased slightly from 49.96% to 50.63%. Deepening its presence for both proprietary brands and specialty pharma portfolio in Asia remains a focus for Hyphens Pharma.

Maintain BUY rating with fair value unchanged at S\$0.370. Our DCF-derived target price translates into a FY21E P/E of 17.5x. Our target price implies a 23.3% upside. We continue to see positives which are i) new product innovation, ii) contribution from more markets and iii) higher margins in 1H on their highest revenue, specialty pharma segment, which will lift FY21E bottomline. We are, however, cautious of the situation at Vietnam (its second biggest geographical contributor) and Malaysia, both of which are still having movement control restrictions, reducing ease of purchase.

Key Risks: Product differentiation, supply chain disruption.

Key Financials

FY ended 31 Dec	FY2018	FY2019	FY2020	FY2021E	FY2022E
Revenue (S\$m)	120.9	119.4	123.7	130.1	134.2
EBIT (S\$m)	7.1	8.0	7.0	7.7	7.8
Net profit (S\$m)	5.4	6.5	6.2	6.3	6.4
Basic EPS (S cents)	1.95	2.17	2.05	2.11	2.14
Dividend per share (S cents)	0.55	0.55	1.00	0.74	0.75
Net cash / (debt)	19.4	25.9	27.5	34.4	38.2
Valuation					
EBIT margin (%)	5.9	6.7	5.7	5.9	5.8
ROIC (%)	27.2	31.0	25.9	31.1	31.2
EV/EBITDA (x)	9.0	6.4	6.9	5.7	5.1
P/E (x)	16.7	13.8	14.6	14.2	14.0
Dividend yield (%)	1.8	1.8	3.3	2.5	2.5

Investment Highlights

Strongest 1H recorded

Revenue (\$'m)	1H21	1H20
Specialty Pharma	34.8	31.4
Proprietary brands	9.4	9.2
Medical hypermart & digital	21.1	21.1
Total	65.4	61.6

Source: Company data

1HFY21 revenue was in line with our forecasts, making up 50.2% of our FY21E revenue. Net profit was higher at 71.1% of our forecasts, as gross margin generated from specialty pharma segment exceeded our expectations due to better product mix.

Revenue saw growth across all segments, rising 6.1% to S\$65.4m, led by specialty pharma principals which grew 10.9% yoy from S\$31.4m to S\$34.8m, with higher demand in Vietnam, Singapore and Malaysia. Proprietary brands (+2.4%) with higher demand for Ceradan products and medical hypermart & digital (+0.4%) saw slight uptick.

Gross margin rose 3.7ppt to 37.9% in 1H21, with higher margins from the specialty pharma segment. Net profit rose 0.8% yoy to S\$4.3m. If government grants were excluded from both periods, net profit grew 22.7% from S\$3.4m to S\$4.2m.

Continue to focus on proprietary brands and internationalization efforts

The Group continues to undergo considerable R&D (S\$0.2m in 1H21, compared to S\$0.07m in 1H20), and has recently launched its Ocean Health® nutritional supplement High Strength Eye Moist Omega Formula to promote moist eyes and healthy vision. Management commented that it was one of their most successful product launches.

As proprietary brands products are developed, marketed and sold by Hyphens, gross margins from the proprietary brands segment is the highest out of the three segments.

Revenue contribution from markets outside Singapore increased slightly from 49.96% to 50.63%. Deepening its presence for both proprietary brands and specialty pharma portfolio in Asia remains a focus for Hyphens Pharma. We remain positive on their overseas expansion, such as through the distribution of Ocean Health in Sri Lanka, Ceradan in China, and TDF Fairence in South Korea, although Management commented that brand recognition and awareness takes time.

Maintain BUY rating with fair value unchanged at S\$0.370

We maintain a BUY rating on Hyphens Pharma, with fair value unchanged at S\$0.370. Our DCF-derived target price translates into a FY21E P/E of 17.5x. Our target price implies a 23.3% upside.

We adjusted FY21E profit estimates slightly (+4.5%) on higher gross margin recorded in 1H with specialty pharma's strong performance, but price in the continued risks of the Delta variant and the elevated cases in key market Vietnam and third highest market Malaysia.

We continue to see positives which are i) new product innovation, ii) contribution from more markets and iii) higher margins in 1H on their highest revenue, specialty pharma segment, which will lift FY21 bottomline. We are, however, cautious of the situation at Vietnam (its second biggest geographical contributor) and Malaysia, both of which are still having movement control restrictions, reducing ease of purchase.

Income Statement

	Fiscal Year Ended 31 Dec				
S\$'mil	FY2018A	FY2019A	FY2020A	FY2021E	FY2022E
Revenue	120.9	119.4	123.7	130.1	134.2
Cost of sales	-80.1	-76.8	-79.9	-85.0	-87.3
Gross profit	40.8	42.7	43.8	45.1	46.9
Interest Income	0.1	0.2	0.2	0.1	0.1
Other income and gains	0.2	0.4	2.2	1.0	0.4
Distribution costs	-21.7	-24.8	-26.5	-27.6	-28.0
Administrative expenses	-10.4	-9.8	-10.1	-10.2	-10.8
Finance costs	-0.1	-0.1	-0.1	-0.1	-0.1
Other losses	-1.8	-0.5	-2.1	-0.7	-0.7
Profit before tax from continuing operations	7.0	8.0	7.1	7.7	7.8
Income tax expense	-1.6	-1.5	-0.9	-1.3	-1.3
Profit, net of tax	5.4	6.5	6.2	6.3	6.4
Earnings Per Share (cents)					
Basic and Diluted	1.95	2.17	2.05	2.11	2.14

Ratios

	Fiscal Year Ended 31 Dec				
	FY2018A	FY2019A	FY2020A	FY2021E	FY2022E
Profitability (%)					
Gross profit/(loss) margin	33.7	35.7	35.4	34.7	35.0
Profit/(loss) before tax margin	5.8	6.7	5.7	5.9	5.8
Liquidity (x)					
Current ratio	1.8	2.0	2.1	2.1	2.2
Quick ratio	1.5	1.7	1.6	1.8	1.9
Interest coverage ratio	55.3	58.9	65.6	70.7	71.8
Net Debt to Equity	Net Cash	Net Cash	Net Cash	Net Cash	Net Cash
Valuation (x)					
P/E	16.7	13.8	14.6	14.2	14.0
P/B	2.3	2.0	1.9	1.8	1.6
EV/EBITDA	9.0	6.4	6.9	5.7	5.1
Cash Conversion Cycle					
Trade receivable days	81	89	86	86	88
Inventory days	49	54	77	53	53
Trade payable days	132	144	144	143	142
CCC days	-2	0	18	-4	-1

Balance Sheet

	Fiscal Year Ended 31 Dec				
S\$'mil	FY2018A	FY2019A	FY2020A	FY2021E	FY2022E
Plant and equipment	3.5	5.9	4.8	4.8	4.7
Intangible assets	7.8	7.5	7.9	8.0	7.9
Deferred tax assets	0.2	0.1	0.0	0.0	0.0
Total non-current assets	11.4	13.5	12.7	12.9	12.7
Inventories	10.9	11.4	16.9	12.3	12.7
Trade and other receivables	29.8	28.7	29.4	31.9	32.9
Prepayments	0.5	0.4	0.6	0.6	0.6
Cash and cash equivalents	22.4	26.2	27.5	34.4	38.2
Total current assets	63.5	66.6	74.4	79.2	84.2
Total assets	75.0	80.1	87.1	92.1	96.9
Share capital	32.6	32.6	32.6	32.6	32.6
Retained earnings	21.6	26.5	29.6	33.7	37.5
Other reserves	-15.0	-15.0	-15.1	-15.1	-15.1
Total equity	39.2	44.1	47.2	51.3	55.0
Deferred tax liabilities	0.5	0.5	0.4	0.4	0.4
Lease liabilities, non-current	0.0	2.4	3.6	3.6	3.6
Total non-current liabilities	0.5	2.9	4.0	4.0	4.0
Total current liabilities	35.3	33.1	36.0	37.1	38.0
Total liabilities	35.8	36.1	40.0	41.1	42.0
Total equity and liabilities	75.0	80.1	87.1	92.3	97.0

Cash Flows Statement

	Fiscal Year Ended 31 Dec				
S\$'mil	FY2018A	FY2019A	FY2020A	FY2021E	FY2022E
Profit/(loss) before tax	7.0	8.0	7.1	7.7	7.8
Amortisation of intangible assets	0.4	0.4	0.4	0.4	0.4
Depreciation of plant and equipment	0.4	1.6	1.7	1.7	1.9
Changes in working capital	-1.3	0.9	-3.8	2.4	-0.4
Others	7.5	9.4	4.1	10.9	8.3
Net cashflows from operating activities	7.5	9.5	4.1	10.9	8.3
Purchase of plant and equipment	-3.3	-0.5	-0.4	-1.5	-2.0
Purchase of intangible assets	-0.0	-0.1	-0.8	-0.3	-0.3
Interest received	0.1	0.2	0.2	0.1	0.1
Net cash flows used in investing activities	-3.3	-0.4	-1.0	-1.7	-2.2
Gross proceeds from IPO	15.6	0.0	0.0	0.0	0.0
Dividends paid to equity owners	-7.0	-1.7	-3.0	-2.2	-2.3
Repayment of borrowings	-4.4	-2.7	0.0	0.0	0.0
Proceeds from borrowings	3.4	0.0	2.1	0.0	0.0
Others	-0.0	-0.0	-0.0	-0.0	-0.0
Net cash flows from (used in) financing activities	5.8	-5.2	-1.8	-2.3	-2.4
Net increase (decrease) in cash and cash equivalents	10.1	3.8	1.4	6.9	3.7
Cash and cash equivalents at beginning	12.3	22.4	26.2	27.5	34.4
Cash and cash equivalents, ending balance	22.4	26.2	27.5	34.4	38.2

DISCLAIMERS AND DISCLOSURES

This report has been prepared and distributed by SAC Capital Private Limited (“**SAC Capital**”) which is a holder of a capital markets services licence and an exempt financial adviser in Singapore.

This report has been prepared for the purpose of general circulation, we have not had regard to the specific investment objectives, financial situation, tax position or unique needs and constraints of any individual person or any specific group of persons and does not purport to be comprehensive or contain all necessary information which a prospective investor may require in arriving at an investment decision. Any prospective purchaser should make his own investigation of the securities and all information provided. Advice should be sought from a financial adviser regarding suitability, taking into account the specific investment objectives, financial situation or particular needs of the person in receipt of the recommendation, before a commitment to purchase is entered into.

This report does not constitute or form part of any offer or solicitation of any offer to buy or sell any securities. This report is confidential and the information in this report shall not be copied or reproduced in part or in whole, and save for the recipient of this report, shall not be disclosed to any other person without the prior written consent of SAC Capital. The distribution of this report outside the jurisdiction of Singapore is also strictly prohibited.

Whereas SAC Capital has not independently verified all the information set out in this report, all reasonable care and effort has been taken to ensure that the facts stated herein are accurate, this report might contain certain forward looking statements and forward looking financial information which are based on certain assumptions and involve known and unknown risks, uncertainties and other factors which may cause the actual results or performance of the subject company to be materially different from those expressed herein. Predictions, projections or forecasts of the economy or market trends are not indicative of the future performance of the subject company. The inclusion of such statements and information should not be regarded as a representation, warranty or prediction with respect to the accuracy of the underlying assumptions of the subject company or that the forecast results will or are likely to be achieved.

Our opinion and facts set out in this report are based on the market, economic, industry and other applicable conditions prevailing as at the date of the preparation of this report. Such conditions may change significantly over a relatively short period of time and we assume no responsibility to update, revise or reaffirm our opinion in light of any development subsequent to the publication of this report, that may or may not have affected our opinion contained herein.

This report contains forward-looking statement which are based on assumptions or forecasts and are subject to uncertainties which may result in the actual result or performance to be materially different from the opinion or facts set out herein. Caution should be exercised in placing undue reliance on such statements. such assumptions or forecasts may change over a relatively short period of time and we assume no responsibility to update, revise or reaffirm our opinion in light of any development subsequent to the publication of this report.

No representation or warranty, expressed or implied, is made and no responsibility is accepted by the company, SAC Capital, or any of their affiliates, advisers or representatives as to the fairness, accuracy, completeness or adequacy of such information or facts, in this report or any other written or oral information made available to any interested party or its advisers and any liability therefore is hereby expressly disclaimed.

SAC Capital and its associates, directors, and/or employees may have positions in the securities covered in the report and may also perform or seek to perform other corporate finance and/or capital markets related services for the company whose securities are covered in the report. SAC Capital and its related companies may from time to time perform advisory services or solicit such advisory services from the entity mentioned in this report (“**Other Services**”). This report is therefore classified as a non-independent report. However, the research professionals involved in the preparation of this report are independent of those possible or actual business relationships as they have not and will not participate in the solicitation or provision of such business.

As at the date of this report, SAC Capital does not have proprietary positions or interests in the subject company, except for:

Party	Quantum of position
Nil	Nil

As at the date of this report, SAC Capital, has had business relations with the subject company within the past 12 months, as disclosed hereunder:

Nature of Business Relation	Date of Business Relation
Continuing Sponsor	Ongoing

As at the date of this report, none of the analysts who covered the securities in this report have any proprietary position or material interest in the subject companies covered here in, except for:

Analyst name	Quantum of position
Nil	Nil

ANALYST CERTIFICATION/REGULATION AC

As noted above, research analyst(s) of SAC Capital who produced this report hereby certify that

- (i) The views expressed in this report accurately reflect his/her personal views about the subject corporation(s);
- (ii) The report was produced independently by him/her;
- (iii) He/she does not on behalf of SAC Capital or any other person carry out Other Services involving any of the subject corporation(s) or securities referred to in this report; and
- (iv) He/she has not received and will not receive any compensation directly or indirectly related to the recommendations or views expressed in this report or to any sales, trading, dealing or corporate finance advisory services or transaction in respect of the securities in this report. He/she has not and will not receive any compensation directly or indirectly linked to the performance of the securities of the subject corporation(s) from the time of the publication of this report either.